GlassScriptPhysician profile
Sridhar H Dasari
NPI 1912991068
$55,524.73
in general payments reported to CMS, 2019-2025
15 companies · $15K in 2025
The $15K reported for 2025 was more than what 94% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,339 · 2020: $15K · 2021: $1,909 · 2022: $6,765 · 2023: $7,680 · 2024: $6,078 · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Honoraria: $4,000 · Travel and Lodging: $2,682 · Food and Beverage: $2,289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,613.50 |
| Honoraria | $4,000.00 |
| Travel and Lodging | $2,681.85 |
| Food and Beverage | $2,289.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $37,239.77 | 2019-2024 | Yupelri, Yupelri |
| Viatris Specialty LLC | $8,099.50 | 2025 | Yupelri |
| Verona Pharma, INC. | $6,382.78 | 2025 | Ohtuvayre |
| Zoll Respicardia, INC. | $2,255.65 | 2024 | Remede System |
| Glaxosmithkline, LLC. | $820.50 | 2019-2025 | Nucala, Benlysta |
| Philips North America LLC | $143.91 | 2022-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Regeneron Healthcare Solutions, INC. | $127.57 | 2025 | Dupixent |
| Genzyme Corporation | $106.95 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $103.79 | 2019-2023 | Uptravi |
| Resmed Corp | $86.00 | 2019 | |
| Inogen, INC. | $66.68 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.87 | 2025 | Ofev |
| Sanofi Pasteur INC. | $24.83 | 2019 | |
| United Therapeutics Corporation | $18.11 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $13.82 | 2024 | Airsupra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sridhar Dasari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.